Patents by Inventor Yuchen Jiao
Yuchen Jiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250073258Abstract: Compositions and methods are provided herein for treating intestinal glycocalyx dysfunction. The composition can comprise a chito-oligosaccharide (COS), and optionally a human milk oligosaccharide (hMO) in an amount sufficient to maintain an intestinal glycocalyx and a pharmaceutically acceptable carrier. The composition can be formulated as an oral dosage form or a parenteral dosage form. The method can comprise identifying intestinal glycocalyx dysfunction in the subject. The method can further comprise administering to the subject a COS in an amount and at a frequency sufficient to prevent, stabilize and reverse damage in the intestinal glycocalyx.Type: ApplicationFiled: November 5, 2024Publication date: March 6, 2025Inventors: Chen CHEN, Edward HOYT, Jianjun LI, Kevin CHEN, Lishi REN, Ming SUN, Siming JIAO, Yuchen ZHANG, Yucheng DU, Yuguang DU, Zhuo WANG
-
Patent number: 12054710Abstract: A method of ctDNA library construction and sequencing data analysis for simultaneously detecting multiple common mutations in liver cancer. The library construction method and sequencing data analysis process have the following advantages: 1. Simultaneous detection of multiple mutation forms in liver cancer without capturing; 2. Suitable for efficient capture of ultra-small target regions; 3. The library may support 10-20 tests; 4. Ligate the DNA barcode to the starting ctDNA molecule during the library construction process, and cooperate with the biological information analysis process to achieve high specific detection of low-frequency mutations in ctDNA; 5. The library is usable for PCR hot spots detection and sequencing by a capture method at the same time, the added DNA barcode may effectively filter out false positive mutations and achieve high-specificity sequencing based on duplex.Type: GrantFiled: April 11, 2019Date of Patent: August 6, 2024Assignees: CANCER HOSPITAL CHINESE ACADEMY OF MEDICAL SCIENCES, GENETRON HEALTH (BEIJING) CO, LTD.Inventors: Yuchen Jiao, Chunfeng Qu, Pei Wang, Kun Chen, Yuting Wang, Qianqian Song, Sizhen Wang, Hai Yan
-
Publication number: 20230272475Abstract: The present invention discloses a method for detecting the mutation and methylation of tumor-specific genes in ctDNA, and this method can simultaneously detect the mutation (including point mutation, insertion-deletion mutation, HBV integration and other mutation forms) and/or methylation of tumor-specific genes in ctDNA in one sample. Not only the sample size requirement is low, but the MC library prepared by this method can support 10-20 subsequent detections. The results of each test can represent the mutation status of all the original ctDNA specimens and the methylation modification status of the region covered by the restriction sites, without reducing the sensitivity and specificity. The present invention has important clinical significance for early tumor screening, disease tracking, efficacy evaluation, prognosis prediction and the like, and has great application value.Type: ApplicationFiled: October 13, 2020Publication date: August 31, 2023Inventors: Yuchen JIAO, Chunfeng QU, Yuting WANG, Pei WANG, Kun CHEN, Qianqian SONG, Hui LIU, Jingjing WANG, Sizhen WANG
-
Publication number: 20220267760Abstract: A method for preparing an amplicon library for detecting the variation in a region to be tested of a target gene of a sample, including the following steps: 1) designing and synthesizing a forward outer primer F1, a forward inner primer F2, and a reverse primer R according to the target region; 2) carrying out a one-step PCR amplification on the sample to be tested using the forward outer primer F1, the forward inner primer F2, and the reverse inner primer R to obtain an amplified product, i.e., the amplicon library of the target region. This one-step library preparation technology can be applied to all second-generation platforms including IonTorrent, illumina and BGI/MGI platforms. Based on the library preparation method, the present invention has developed detection products for SNP, Ins/Del, CNV and methylation of DNA, as well as detection products for s gene fusion and expression of RNA samples.Type: ApplicationFiled: July 28, 2020Publication date: August 25, 2022Inventors: Qiaosong ZHENG, Xiao SHI, Yuchen JIAO, Min CHEN, Kaihua ZHANG, Sizhen WANG, Hai YAN
-
Publication number: 20220145399Abstract: The present invention provides a kit for early screening of hepatocellular carcinoma, comprising a gene marker detection reagent and a protein marker detection reagent. The invention also provides a preparation method and application of the kit. The kit comprising specific gene markers and protein markers of the present invention has been demonstrated to be effective in achieving early screening of HCC in community populations, particularly in prospective studies.Type: ApplicationFiled: September 17, 2019Publication date: May 12, 2022Inventors: Yuchen JIAO, Chunfeng QU, Yuting WANG, Pei WANG, Kun CHEN, Qianqian SONG, Hui LIU, Sizhen WANG, Hai YAN
-
Publication number: 20220119806Abstract: A method of ctDNA library construction and sequencing data analysis for simultaneously detecting multiple common mutations in liver cancer. The library construction method and sequencing data analysis process have the following advantages: 1. Simultaneous detection of multiple mutation forms in liver cancer without capturing; 2. Suitable for efficient capture of ultra-small target regions; 3. The library may support 10-20 tests; 4. Ligate the DNA barcode to the starting ctDNA molecule during the library construction process, and cooperate with the biological information analysis process to achieve high specific detection of low-frequency mutations in ctDNA; 5. The library is usable for PCR hot spots detection and sequencing by a capture method at the same time, the added DNA barcode may effectively filter out false positive mutations and achieve high-specificity sequencing based on duplex.Type: ApplicationFiled: April 11, 2019Publication date: April 21, 2022Inventors: Yuchen JIAO, Chunfeng QU, Pei WANG, Kun CHEN, Yuting WANG, Qianqian SONG, Sizhen WANG, Hai YAN
-
Patent number: 11306364Abstract: We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (?15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.Type: GrantFiled: July 14, 2020Date of Patent: April 19, 2022Assignees: Duke University, The Johns Hopkins UniversityInventors: Hai Yan, Bert Vogelstein, Nickolas Papadopoulos, Kenneth W. Kinzler, Yuchen Jiao, Chetan Bettegowda, Darell D. Bigner, Zachary J. Reitman, Patrick J. Killela
-
Patent number: 11254988Abstract: We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.Type: GrantFiled: May 25, 2018Date of Patent: February 22, 2022Assignees: The Johns Hopkins University, Duke UniversityInventors: Hai Yan, Darell Bigner, Bert Vogelstein, Kenneth W. Kinzler, Alan Meeker, Ralph Hruban, Nickolas Papadopoulos, Luis Diaz, Yuchen Jiao
-
Patent number: 11155862Abstract: The present invention discloses a method for rapidly constructing amplicon library including the following steps: 1. Synthesizing a primer combination for constructing an amplicon library of a DNA sample, the primer combination of the amplicon library used to construct the DNA sample includes: a forward fusion primer designed according to the target amplicon, a reverse fusion primer designed according to the target amplicon, a forward universal primer and a reverse universal primer; 2. Constructing a PCR reaction system for the DNA sample; 3. Performing PCR. The method according to the present invention can be used to construct an amplicon library in a simple and rapid manner, and since a barcode is introduced before the start of PCR, the possibility of cross-contamination between the sample and the library is greatly reduced.Type: GrantFiled: March 28, 2018Date of Patent: October 26, 2021Assignee: Genetron Health (Beijing) Co., Ltd.Inventors: Hai Yan, Sizhen Wang, Yuchen Jiao, Dayong Xu, Qiaosong Zheng, Xiao Shi
-
Publication number: 20200399708Abstract: We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (?15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.Type: ApplicationFiled: July 14, 2020Publication date: December 24, 2020Applicants: Duke University, The Johns Hopkins UniversityInventors: Hai Yan, Bert Vogelstein, Nickolas Papadopoulos, Kenneth W. Kinzler, Yuchen Jiao, Chetan Bettegowda, Darell D. Bigner, Zachary J. Reitman, Patrick J. Killela
-
Patent number: 10711310Abstract: We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (?15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.Type: GrantFiled: February 18, 2014Date of Patent: July 14, 2020Assignees: Duke University, The Johns Hopkins UniversityInventors: Hai Yan, Bert Vogelstein, Nickolas Papadopoulos, Kenneth W. Kinzler, Yuchen Jiao, Chetan Bettegowda, Darell D. Bigner, Zachary J. Reitman, Patrick J. Killela
-
Publication number: 20190352711Abstract: The present invention discloses a method for rapidly constructing amplicon library including the following steps: 1. Synthesizing a primer combination for constructing an amplicon library of a DNA sample, the primer combination of the amplicon library used to construct the DNA sample includes: an upstream fusion primer designed according to the target amplicon, a downstream fusion primer designed according to the target amplicon, an upstream universal primer and a downstream universal primer; 2. Constructing a PCR reaction system for the DNA sample; 3. Performing PCR. The method according to the present invention can be used to construct an amplicon library in a simple and rapid manner, and since a barcode is introduced before the start of PCR, the possibility of cross-contamination between the sample and the library is greatly reduced.Type: ApplicationFiled: March 28, 2018Publication date: November 21, 2019Inventors: Hai Yan, Sizhen Wang, Yuchen Jiao, Dayong Xu, Qiaosong Zheng, Xiao Shi
-
Publication number: 20190055610Abstract: Pancreatic Neuroendocrine Tumors (PanNETs) are a rare but clinically important form of pancreatic neoplasia. To explore the genetic basis of PanNETs, we determined the exomic sequences of ten non-familial PanNETs and then screened the most commonly mutated genes in 58 additional PanNETs. Remarkably, the most frequently mutated genes specify proteins implicated in chromatin remodeling: 44% of the tumors had somatic inactivating mutations in MEN-1, which encodes menin, a component of a histone methyltransferase complex; and 43% had mutations in genes encoding either of the two subunits of a transcription/chromatin remodeling complex consisting of DAXX (death-domain associated protein) and ATRX (alpha thalassemia/mental retardation syndrome X-linked). Clinically, mutations in the MEN1 and DAXX/ATRX genes were associated with better prognosis.Type: ApplicationFiled: November 2, 2018Publication date: February 21, 2019Inventors: Bert Vogelstein, Kenneth W. Kinzler, Victor Velculescu, Luis Diaz, Nickolas Papadopoulos, Yuchen Jiao, Ralph Hruban
-
Patent number: 10144971Abstract: Pancreatic Neuroendocrine Tumors (PanNETs) are a rare but clinically important form of pancreatic neoplasia. To explore the genetic basis of PanNETs, we determined the exomic sequences of ten non-familial PanNETs and then screened the most commonly mutated genes in 58 additional PanNETs. Remarkably, the most frequently mutated genes specify proteins implicated in chromatin remodeling: 44% of the tumors had somatic inactivating mutations in MEN-1, which encodes menin, a component of a histone methyltransferase complex; and 43% had mutations in genes encoding either of the two subunits of a transcription/chromatin remodeling complex consisting of DAXX (death-domain associated protein) and ATRX (alpha thalassemia/mental retardation syndrome X-linked). Clinically, mutations in the MEN1 and DAXX/ATRX genes were associated with better prognosis.Type: GrantFiled: January 4, 2012Date of Patent: December 4, 2018Assignee: The Johns Hopkins UniversityInventors: Bert Vogelstein, Kenneth W Kinzler, Victor Velculescu, Luis Diaz, Nikolas Papadopoulos, Yuchen Jiao, Ralph Hruban
-
Publication number: 20180334726Abstract: We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.Type: ApplicationFiled: May 25, 2018Publication date: November 22, 2018Inventors: Hai Yan, Darell Bigner, Bert Vogelstein, Kenneth W. Kinzler, Alan Meeker, Ralph Hruban, Nickolas Papadopoulos, Luis Diaz, Yuchen Jiao
-
Patent number: 9982306Abstract: We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.Type: GrantFiled: June 28, 2012Date of Patent: May 29, 2018Assignees: Duke University, The Johns Hopkins UniversityInventors: Hai Yan, Darell Bigner, Bert Vogelstein, Kenneth W. Kinzler, Alan Meeker, Ralph Hruban, Nickolas Papadopoulos, Luis Diaz, Yuchen Jiao
-
Publication number: 20150361507Abstract: We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (?15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.Type: ApplicationFiled: February 18, 2014Publication date: December 17, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Hai YAN, Bert VOGELSTEIN, Nickolas PAPADOPOULOS, Kenneth W. KINZLER, Yuchen JIAO, Chetan BETTEGOWDA, Darell D. BIGNER
-
Publication number: 20140227271Abstract: We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.Type: ApplicationFiled: June 28, 2012Publication date: August 14, 2014Applicants: DUKE UNIVERSITY, THE JOHNS HOPKINS UNIVERSITYInventors: Hai Yan, Darell Bigner, Bert Vogelstein, Kenneth W. Kinzler, Alan Meeker, Ralph Hruban, Nickolas Papadopoulos, Luis Diaz, Yuchen Jiao
-
Publication number: 20140045881Abstract: Pancreatic Neuroendocrine Tumors (PanNETs) are a rare but clinically important form of pancreatic neoplasia. To explore the genetic basis of PanNETs, we determined the exomic sequences of ten non-familial PanNETs and then screened the most commonly mutated genes in 58 additional PanNETs. Remarkably, the most frequently mutated genes specify proteins implicated in chromatin remodeling: 44% of the tumors had somatic inactivating mutations in MEN-1, which encodes menin, a component of a histone methyltransferase complex; and 43% had mutations in genes encoding either of the two subunits of a transcription/chromatin remodeling complex consisting of DAXX (death-domain associated protein) and ATRX (alpha thalassemia/mental retardation syndrome X-linked). Clinically, mutations in the MEN1 and DAXX/ATRX genes were associated with better prognosis.Type: ApplicationFiled: January 4, 2012Publication date: February 13, 2014Applicant: The Johns Hopkins UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, Victor Velculescu, Luis Diaz, Nikolas Papadopoulos, Yuchen Jiao, Ralph Hruban